FPI-2265-203
FPI-2265-203: A Phase II, Open-Label, Multi-Centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Trial summary:
Receptor status / problem studied:
Inclusion criteria
Exclusion criteria
Open for recruitment
Trial Title
FPI-2265-203
Diagnosis
Prostate cancer
Type of trial
Pharmaceutical
Type of treatement
Medical Oncology
Phase
II
Locations
Investigators
Principal Investigator